CA2501111A1 - Procedes et systemes permettant d'identifier des composants de reseaux biochimiques mammaliens comme etant des cibles d'agents therapeutiques - Google Patents
Procedes et systemes permettant d'identifier des composants de reseaux biochimiques mammaliens comme etant des cibles d'agents therapeutiques Download PDFInfo
- Publication number
- CA2501111A1 CA2501111A1 CA002501111A CA2501111A CA2501111A1 CA 2501111 A1 CA2501111 A1 CA 2501111A1 CA 002501111 A CA002501111 A CA 002501111A CA 2501111 A CA2501111 A CA 2501111A CA 2501111 A1 CA2501111 A1 CA 2501111A1
- Authority
- CA
- Canada
- Prior art keywords
- network
- components
- cell
- igf
- recited
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 221
- 239000003814 drug Substances 0.000 title abstract description 37
- 229940124597 therapeutic agent Drugs 0.000 title abstract description 18
- 210000004027 cell Anatomy 0.000 claims abstract description 312
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 285
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 151
- 238000004088 simulation Methods 0.000 claims abstract description 76
- 230000003993 interaction Effects 0.000 claims abstract description 61
- 230000000694 effects Effects 0.000 claims abstract description 59
- 230000001413 cellular effect Effects 0.000 claims abstract description 42
- 230000007704 transition Effects 0.000 claims abstract description 13
- 210000003850 cellular structure Anatomy 0.000 claims abstract description 3
- 239000000126 substance Substances 0.000 claims description 83
- 238000004422 calculation algorithm Methods 0.000 claims description 61
- 230000006907 apoptotic process Effects 0.000 claims description 47
- 201000010099 disease Diseases 0.000 claims description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
- 230000014509 gene expression Effects 0.000 claims description 46
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 45
- 101150017888 Bcl2 gene Proteins 0.000 claims description 44
- 238000005457 optimization Methods 0.000 claims description 43
- 206010028980 Neoplasm Diseases 0.000 claims description 40
- 230000008859 change Effects 0.000 claims description 37
- 230000003094 perturbing effect Effects 0.000 claims description 37
- 201000011510 cancer Diseases 0.000 claims description 35
- 238000004458 analytical method Methods 0.000 claims description 30
- 238000002474 experimental method Methods 0.000 claims description 25
- 230000035790 physiological processes and functions Effects 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 230000035945 sensitivity Effects 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 230000002829 reductive effect Effects 0.000 claims description 14
- 230000018199 S phase Effects 0.000 claims description 13
- 108090000397 Caspase 3 Proteins 0.000 claims description 8
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 claims description 7
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 239000011159 matrix material Substances 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 6
- 238000002493 microarray Methods 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 238000005070 sampling Methods 0.000 claims description 2
- 102000016736 Cyclin Human genes 0.000 claims 3
- 108050006400 Cyclin Proteins 0.000 claims 3
- 239000003550 marker Substances 0.000 claims 3
- 102000003952 Caspase 3 Human genes 0.000 claims 1
- 238000013459 approach Methods 0.000 abstract description 11
- 230000002596 correlated effect Effects 0.000 abstract 1
- 101100174785 Bacillus subtilis (strain 168) ganS gene Proteins 0.000 description 410
- 101150108006 cycB gene Proteins 0.000 description 410
- 101150030271 AXIN1 gene Proteins 0.000 description 236
- 102000051172 Axin Human genes 0.000 description 236
- 108700012045 Axin Proteins 0.000 description 236
- 101100382166 Nitrosomonas europaea (strain ATCC 19718 / CIP 103999 / KCTC 2705 / NBRC 14298) cycA3 gene Proteins 0.000 description 203
- 101150052102 cycA gene Proteins 0.000 description 203
- 101150106538 pscC gene Proteins 0.000 description 203
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 166
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 166
- 102000011781 Karyopherins Human genes 0.000 description 130
- 108010062228 Karyopherins Proteins 0.000 description 130
- 235000018102 proteins Nutrition 0.000 description 121
- 101150033270 Gadd45a gene Proteins 0.000 description 116
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 114
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 105
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 105
- 238000006243 chemical reaction Methods 0.000 description 98
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 89
- 102000055102 bcl-2-Associated X Human genes 0.000 description 79
- 108700000707 bcl-2-Associated X Proteins 0.000 description 79
- 102100026548 Caspase-8 Human genes 0.000 description 76
- 108020004999 messenger RNA Proteins 0.000 description 73
- 101100112682 Danio rerio ccne1 gene Proteins 0.000 description 61
- 229940125396 insulin Drugs 0.000 description 57
- 102000004877 Insulin Human genes 0.000 description 56
- 108090001061 Insulin Proteins 0.000 description 56
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 55
- 238000009739 binding Methods 0.000 description 53
- 102000013814 Wnt Human genes 0.000 description 52
- 108050003627 Wnt Proteins 0.000 description 52
- 102100038576 F-box/WD repeat-containing protein 1A Human genes 0.000 description 43
- 101001030691 Homo sapiens F-box/WD repeat-containing protein 1A Proteins 0.000 description 43
- 230000006870 function Effects 0.000 description 38
- 230000008569 process Effects 0.000 description 36
- 101150073031 cdk2 gene Proteins 0.000 description 34
- 108700000712 BH3 Interacting Domain Death Agonist Proteins 0.000 description 33
- 102000055105 BH3 Interacting Domain Death Agonist Human genes 0.000 description 33
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 31
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 31
- 239000003112 inhibitor Substances 0.000 description 30
- 230000037361 pathway Effects 0.000 description 29
- 101150006084 CHKB gene Proteins 0.000 description 28
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 description 26
- 101150012716 CDK1 gene Proteins 0.000 description 24
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 24
- 101710181403 Frizzled Proteins 0.000 description 23
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 22
- 230000035772 mutation Effects 0.000 description 22
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 21
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 21
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 21
- 230000022131 cell cycle Effects 0.000 description 21
- 208000029742 colonic neoplasm Diseases 0.000 description 21
- 238000013518 transcription Methods 0.000 description 21
- 230000035897 transcription Effects 0.000 description 21
- 206010009944 Colon cancer Diseases 0.000 description 20
- 230000004913 activation Effects 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 20
- 230000019491 signal transduction Effects 0.000 description 20
- 230000001965 increasing effect Effects 0.000 description 19
- 238000005259 measurement Methods 0.000 description 17
- 239000012528 membrane Substances 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 16
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 16
- 230000006399 behavior Effects 0.000 description 16
- 238000006731 degradation reaction Methods 0.000 description 16
- 210000004940 nucleus Anatomy 0.000 description 16
- 230000015556 catabolic process Effects 0.000 description 15
- 239000003102 growth factor Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 15
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 15
- 102400001368 Epidermal growth factor Human genes 0.000 description 14
- 101800003838 Epidermal growth factor Proteins 0.000 description 14
- 102000003964 Histone deacetylase Human genes 0.000 description 14
- 108090000353 Histone deacetylase Proteins 0.000 description 14
- 238000010586 diagram Methods 0.000 description 14
- 229940116977 epidermal growth factor Drugs 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 108060000903 Beta-catenin Proteins 0.000 description 13
- 102000015735 Beta-catenin Human genes 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 13
- 230000026731 phosphorylation Effects 0.000 description 13
- 238000006366 phosphorylation reaction Methods 0.000 description 13
- 238000002922 simulated annealing Methods 0.000 description 13
- 230000014616 translation Effects 0.000 description 13
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 12
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 12
- 108010025020 Nerve Growth Factor Proteins 0.000 description 12
- 102000015336 Nerve Growth Factor Human genes 0.000 description 12
- 108091000080 Phosphotransferase Proteins 0.000 description 12
- 239000013626 chemical specie Substances 0.000 description 12
- 229940053128 nerve growth factor Drugs 0.000 description 12
- 102000020233 phosphotransferase Human genes 0.000 description 12
- 238000013519 translation Methods 0.000 description 12
- 102000040945 Transcription factor Human genes 0.000 description 11
- 108091023040 Transcription factor Proteins 0.000 description 11
- 230000011664 signaling Effects 0.000 description 11
- 108010006519 Molecular Chaperones Proteins 0.000 description 10
- 230000010354 integration Effects 0.000 description 10
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 9
- 238000013178 mathematical model Methods 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 102100029855 Caspase-3 Human genes 0.000 description 8
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 8
- 238000005842 biochemical reaction Methods 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 230000004850 protein–protein interaction Effects 0.000 description 8
- 238000004064 recycling Methods 0.000 description 8
- 230000009466 transformation Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000008267 autocrine signaling Effects 0.000 description 7
- 238000005183 dynamical system Methods 0.000 description 7
- 230000004807 localization Effects 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- -1 1972 Substances 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108010042653 IgA receptor Proteins 0.000 description 6
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000003470 mitochondria Anatomy 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 230000003827 upregulation Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 5
- 101150089023 FASLG gene Proteins 0.000 description 5
- 102000054184 GADD45 Human genes 0.000 description 5
- 101001066158 Homo sapiens Growth arrest and DNA damage-inducible protein GADD45 alpha Proteins 0.000 description 5
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 210000000805 cytoplasm Anatomy 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- 102000011727 Caspases Human genes 0.000 description 4
- 108010076667 Caspases Proteins 0.000 description 4
- 101150117962 DUSP1 gene Proteins 0.000 description 4
- 102100034428 Dual specificity protein phosphatase 1 Human genes 0.000 description 4
- 101710134671 Executioner caspase Proteins 0.000 description 4
- 101150012093 MKP1 gene Proteins 0.000 description 4
- 238000000342 Monte Carlo simulation Methods 0.000 description 4
- 101100478343 Schizosaccharomyces pombe (strain 972 / ATCC 24843) srk1 gene Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000003305 autocrine Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 238000004364 calculation method Methods 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000005094 computer simulation Methods 0.000 description 4
- 210000000172 cytosol Anatomy 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229940000406 drug candidate Drugs 0.000 description 4
- 238000009509 drug development Methods 0.000 description 4
- 102000034356 gene-regulatory proteins Human genes 0.000 description 4
- 108091006104 gene-regulatory proteins Proteins 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000007620 mathematical function Methods 0.000 description 4
- 230000011278 mitosis Effects 0.000 description 4
- 231100000590 oncogenic Toxicity 0.000 description 4
- 230000002246 oncogenic effect Effects 0.000 description 4
- 210000003463 organelle Anatomy 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- 108091028690 C-myc mRNA Proteins 0.000 description 3
- 102000004091 Caspase-8 Human genes 0.000 description 3
- 108090000538 Caspase-8 Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000206602 Eukaryota Species 0.000 description 3
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 3
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 3
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 3
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 3
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 3
- 101100482130 Xenopus laevis fbxw1 gene Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000012443 analytical study Methods 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 101150113535 chek1 gene Proteins 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000007418 data mining Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000012912 drug discovery process Methods 0.000 description 3
- 239000003596 drug target Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000016507 interphase Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000005312 nonlinear dynamic Methods 0.000 description 3
- 230000005522 programmed cell death Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 230000003362 replicative effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 108091008743 testicular receptors 4 Proteins 0.000 description 3
- 230000034512 ubiquitination Effects 0.000 description 3
- 238000010798 ubiquitination Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 208000032325 CEBPE-associated autoinflammation-immunodeficiency-neutrophil dysfunction syndrome Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000004039 Caspase-9 Human genes 0.000 description 2
- 108090000566 Caspase-9 Proteins 0.000 description 2
- 102000016362 Catenins Human genes 0.000 description 2
- 108010067316 Catenins Proteins 0.000 description 2
- 102000003910 Cyclin D Human genes 0.000 description 2
- 108090000259 Cyclin D Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 2
- 206010024796 Logorrhoea Diseases 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100173416 Mus musculus Btrc gene Proteins 0.000 description 2
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 2
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 2
- 102000004357 Transferases Human genes 0.000 description 2
- 108090000992 Transferases Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000003281 allosteric effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 108700000711 bcl-X Proteins 0.000 description 2
- 102000055104 bcl-X Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008238 biochemical pathway Effects 0.000 description 2
- 230000009141 biological interaction Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 238000006757 chemical reactions by type Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- FDAKNRLXSJBEFL-UHFFFAOYSA-N dicyclohexyl-[2-propan-2-yloxy-6-[2,4,6-tri(propan-2-yl)phenyl]phenyl]phosphane Chemical compound CC(C)Oc1cccc(c1P(C1CCCCC1)C1CCCCC1)-c1c(cc(cc1C(C)C)C(C)C)C(C)C FDAKNRLXSJBEFL-UHFFFAOYSA-N 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 238000004836 empirical method Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YYJNOYZRYGDPNH-MFKUBSTISA-N fenpyroximate Chemical group C=1C=C(C(=O)OC(C)(C)C)C=CC=1CO/N=C/C=1C(C)=NN(C)C=1OC1=CC=CC=C1 YYJNOYZRYGDPNH-MFKUBSTISA-N 0.000 description 2
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 108010041420 microbial alkaline proteinase inhibitor Proteins 0.000 description 2
- 238000004377 microelectronic Methods 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 101150015886 nuc-1 gene Proteins 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 230000005937 nuclear translocation Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000000861 pro-apoptotic effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000022983 regulation of cell cycle Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010206 sensitivity analysis Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 238000004800 variational method Methods 0.000 description 2
- 238000001086 yeast two-hybrid system Methods 0.000 description 2
- YQGHJCYLMLPCCB-UHFFFAOYSA-N 2,4-diaminopyrimidin-5-ol Chemical compound NC1=NC=C(O)C(N)=N1 YQGHJCYLMLPCCB-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000007299 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- 101000587984 Arabidopsis thaliana Protein SPOROCYTELESS Proteins 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 101150050673 CHK1 gene Proteins 0.000 description 1
- 101100220147 Caenorhabditis elegans cdkl-1 gene Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 241001071944 Cyta Species 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101150043714 DUSP6 gene Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100010535 Drosophila melanogaster Mkp3 gene Proteins 0.000 description 1
- 101100412394 Drosophila melanogaster Reg-2 gene Proteins 0.000 description 1
- 102100027274 Dual specificity protein phosphatase 6 Human genes 0.000 description 1
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 1
- 102000005698 Frizzled receptors Human genes 0.000 description 1
- 108010045438 Frizzled receptors Proteins 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 101150002416 Igf2 gene Proteins 0.000 description 1
- 241000713321 Intracisternal A-particles Species 0.000 description 1
- 102100027670 Islet amyloid polypeptide Human genes 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- GVOIQSXBMLNCLC-UHFFFAOYSA-N OOOS Chemical compound OOOS GVOIQSXBMLNCLC-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 description 1
- 108050004017 Ras GTPase-activating protein 1 Proteins 0.000 description 1
- 102000042463 Rho family Human genes 0.000 description 1
- 108091078243 Rho family Proteins 0.000 description 1
- 101710184528 Scaffolding protein Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
- 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 240000006909 Tilia x europaea Species 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 229940123468 Transferase inhibitor Drugs 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000005756 apoptotic signaling Effects 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 102000013515 cdc42 GTP-Binding Protein Human genes 0.000 description 1
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 101150090422 gsk-3 gene Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000035773 mitosis phase Effects 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108091006026 monomeric small GTPases Proteins 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 238000003909 pattern recognition Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000004654 survival pathway Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/30—Dynamic-time models
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4739—Cyclin; Prad 1
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/10—Boolean models
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/20—Probabilistic models
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- General Health & Medical Sciences (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33599901P | 2001-11-02 | 2001-11-02 | |
| US60/335,999 | 2001-11-02 | ||
| US40676402P | 2002-08-29 | 2002-08-29 | |
| US60/406,764 | 2002-08-29 | ||
| US10/286,372 | 2002-11-01 | ||
| US10/286,372 US20030144823A1 (en) | 2001-11-01 | 2002-11-01 | Scale-free network inference methods |
| PCT/US2002/035301 WO2003040992A1 (fr) | 2001-11-02 | 2002-11-04 | Procedes et systemes permettant d'identifier des composants de reseaux biochimiques mammaliens comme etant des cibles d'agents therapeutiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2501111A1 true CA2501111A1 (fr) | 2003-05-15 |
Family
ID=27403609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002501111A Abandoned CA2501111A1 (fr) | 2001-11-02 | 2002-11-04 | Procedes et systemes permettant d'identifier des composants de reseaux biochimiques mammaliens comme etant des cibles d'agents therapeutiques |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1454282A4 (fr) |
| CA (1) | CA2501111A1 (fr) |
| WO (1) | WO2003040992A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7069534B2 (en) | 2003-12-17 | 2006-06-27 | Sahouria Emile Y | Mask creation with hierarchy management using cover cells |
| US8554486B2 (en) | 2004-02-20 | 2013-10-08 | The Mathworks, Inc. | Method, computer program product, and apparatus for selective memory restoration of a simulation |
| US7844431B2 (en) | 2004-02-20 | 2010-11-30 | The Mathworks, Inc. | Method and apparatus for integrated modeling, simulation and analysis of chemical and biochemical reactions |
| WO2007002895A1 (fr) * | 2005-06-29 | 2007-01-04 | Board Of Trustees Of Michigan State University | Structure d'integration utilisee dans la recherche d'une voie d'integration en trois etapes |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5930154A (en) * | 1995-01-17 | 1999-07-27 | Intertech Ventures, Ltd. | Computer-based system and methods for information storage, modeling and simulation of complex systems organized in discrete compartments in time and space |
| US5914891A (en) * | 1995-01-20 | 1999-06-22 | Board Of Trustees, The Leland Stanford Junior University | System and method for simulating operation of biochemical systems |
| US6165709A (en) * | 1997-02-28 | 2000-12-26 | Fred Hutchinson Cancer Research Center | Methods for drug target screening |
| US5965352A (en) * | 1998-05-08 | 1999-10-12 | Rosetta Inpharmatics, Inc. | Methods for identifying pathways of drug action |
| US6132969A (en) * | 1998-06-19 | 2000-10-17 | Rosetta Inpharmatics, Inc. | Methods for testing biological network models |
| WO2000023933A1 (fr) * | 1998-10-21 | 2000-04-27 | Bios Group Lp | Systemes et procedes d'analyse de reseaux genetiques |
| US6203987B1 (en) * | 1998-10-27 | 2001-03-20 | Rosetta Inpharmatics, Inc. | Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns |
| US20020068269A1 (en) * | 2000-03-10 | 2002-06-06 | Allen Eric B. | System and method for simulating cellular biochemical pathways |
| AU2001256585A1 (en) * | 2000-04-14 | 2001-10-30 | Hybrigenics S.A. | Method for constructing, representing or displaying protein interaction maps |
| EP2051177A1 (fr) * | 2001-02-09 | 2009-04-22 | The Trustees of Columbia University in the City of New York | Procédé de prédiction de réseaux d'interaction moléculaire |
-
2002
- 2002-11-04 WO PCT/US2002/035301 patent/WO2003040992A1/fr not_active Ceased
- 2002-11-04 CA CA002501111A patent/CA2501111A1/fr not_active Abandoned
- 2002-11-04 EP EP02773968A patent/EP1454282A4/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003040992A1 (fr) | 2003-05-15 |
| EP1454282A4 (fr) | 2005-04-06 |
| EP1454282A1 (fr) | 2004-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7415359B2 (en) | Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents | |
| Ruiz et al. | Identification of disease treatment mechanisms through the multiscale interactome | |
| Douglass et al. | A community challenge for a pancancer drug mechanism of action inference from perturbational profile data | |
| Tang et al. | Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles | |
| Zhu et al. | Getting connected: analysis and principles of biological networks | |
| US20040088116A1 (en) | Methods and systems for creating and using comprehensive and data-driven simulations of biological systems for pharmacological and industrial applications | |
| Tee et al. | Exploring the allosteric territory of protein function | |
| US20040024772A1 (en) | Method of foming molecular function network | |
| Lameijer et al. | Evolutionary algorithms in drug design | |
| Chang et al. | Antibacterial mechanisms identified through structural systems pharmacology | |
| Borsatto et al. | SWISH-X, an Expanded Approach to Detect Cryptic Pockets in Proteins and at Protein–Protein Interfaces | |
| BS et al. | Vitamin D analog calcitriol for breast cancer therapy; an integrated drug discovery approach | |
| US20050130192A1 (en) | Apparatus and method for identifying therapeutic targets using a computer model | |
| Gao et al. | Quantitative utilization of prior biological knowledge in the Bayesian network modeling of gene expression data | |
| CA2501111A1 (fr) | Procedes et systemes permettant d'identifier des composants de reseaux biochimiques mammaliens comme etant des cibles d'agents therapeutiques | |
| Watson et al. | Using multilayer heterogeneous networks to infer functions of phosphorylated sites | |
| Pan et al. | Elements of Computational Systems Biology | |
| Sharma et al. | Evolutionary algorithms and artificial intelligence in drug discovery: opportunities, tools, and prospects | |
| Torielli et al. | Integrating Protein Interaction Surface Prediction with a Fragment-Based Drug Design: Automatic Design of New Leads with Fragments on Energy Surfaces | |
| Xie et al. | DeepMPSF: a deep learning network for predicting general protein phosphorylation sites based on multiple protein sequence features | |
| Meyerhöfer et al. | Inference of differential kinase interaction networks with KINference | |
| US20030014232A1 (en) | Methods for predicting biological activities of cellular constituents | |
| Peirce et al. | Multiscale biosystems integration: coupling intracellular network analysis with tissue-patterning simulations | |
| Wang et al. | mNSF: multi-sample non-negative spatial factorization | |
| Daigle Jr et al. | Current progress in static and dynamic modeling of biological networks |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20121105 |